COSMOS HEALTH INC

Cosmos Health CEO swaps debt for shares, boosting his stake to 13 % and cutting leverage—investors weigh governance impact versus potential upside.

Cosmos Health CFO’s fresh 168k‑share buy signals growing insider confidence as the nutraceutical “18 Series” platform gears toward revenue, offering a hopeful turn for a discount‑price, growth‑stage stock.

CEO Siokas Grigorios buys 218k Cosmos Health shares via a debt‑exchange, signalling confidence amid a steep price dip and a planned Doc Pharma acquisition.

Cosmos Health insider buying signals confidence in new contract‑manufacturing deals, hinting at possible upside despite current market weakness.

CEO Siokas Grigorios’s latest insider buy at Cosmos Health raises hopes for a strategic pivot and stronger liquidity amid a volatile, low‑priced stock.

Cosmos Health CEO’s insider buying sparks debate: 291k shares bought at $0.41, debt‑to‑equity swap, and what it means for investors.

CEO Siokas Grigorios buys 353,321 Cosmos Health shares, swapping debt for equity to boost confidence and strengthen the company’s balance sheet.

Cosmos Health CEO’s insider buying spree signals confidence yet investors must weigh weak fundamentals and upcoming earnings for true growth insight.

CEO Siokas Grigorios’s fresh $57k share purchase boosts Cosmos Health’s insider confidence, sparking online buzz amid a promising PathMuscle partnership.

CEO Siokas Grigorios’s latest buy at Cosmos Health shows bullish confidence while a debt‑to‑equity swap strengthens the balance sheet—what’s next for the stock?